Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren't as impressive as those promised ...

Key Takeaways Real-world results with weight-loss drugs aren’t as impressive as those in clinical trialsClinic patients ...

A Cleveland Clinic study shows that semaglutide and tirzepatide – injectable GLP-1 drugs for obesity – produce smaller weight ...

WEDNESDAY, May 28, 2025 (HealthDay News) — For adults with diabetes and obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with a reduced risk for obesity-related cancer ...

The number of people prescribed GLP-1 drugs for weight management has skyrocketed over the past five years, according to new data from FAIR Health. The report found that just over 2% of adults in ...

Positive Topline Efficacy Results for the Phase 2b QUALITY Clinical Study: Enobosarm in Combination with GLP-1 RA Drugs Makes Weight Reduction More ... and hemoglobin A1c at 24 weeks.

GLP-1 agonist medications, such as Ozempic and Wegovy, are gaining widespread attention for their effectiveness in managing type 2 diabetes and supporting weight reduction ... have resorted to ...

in the combined therapy group showed a trend of BMI reduction and possible acetazolamide dose reduction following GLP-1 use after a year. Glucagon-like peptide 1 (GLP-1) receptor agonists (RA) can ...

We have learned that many of the GLP-1 benefits in humans are also weight ... any drugs in diabetes that reduced MACE, and now, a 22% reduction, nah, we’re going to pull it from the market ...

The overall safety profile of the mazdutide group was consistent with findings from previous studies of mazdutide and aligned with that of other GLP-1 receptor agonists. The most frequently ...